Rutherford Health - Rutherford Health signs partnership with OncoDNA
RNS Number : 9140H
Rutherford Health PLC
09 August 2021

Rutherford Health Plc

Partnership with OncoDNA to provide Rutherford patients with genomic testing


9 August 2021: Rutherford Health plc (AQSE: RUTH, the "Group"), a healthcare group committed to providing innovative cancer care of the highest quality, announces a partnership with OncoDNA, a genomic and theranostic company specialising in precision medicine for the treatment of cancer and genetic diseases. The partnership will provide Rutherford cancer patients with access to the latest genomic testing and support the accessibility and development of these tests within the UK.

Comprehensive genomic tests help oncologists and cancer patients identify the most effective therapy for them, as well as monitor disease progression and therapeutic response. The collaboration, named OncoDNA@theRutherford, combines OncoDNA's expertise in precision oncology and cutting-edge biomarker tests on both solid and liquid biopsies with Rutherford Health's UK network of advanced centres and team of leading oncologists.

This partnership will allow cancer patients who are eligible to access a more tailored approach to their cancer treatment, supporting better clinical outcomes.


Mike Moran, CEO of Rutherford Health Plc, said:

"This partnership with OncoDNA will be key in bringing a personalised approach to our patient's treatments. Doctors will now be able to offer treatments that are best suited to the genetic and genomic characteristics of the patient's tumour.


"Rutherford Health is at the forefront of research and scientific advances in oncology and we play a major role in expanding access to the most advanced cancer treatments, enabling 'precision medicine' in the UK. This partnership will also help Rutherford's extensive network of oncologists build their understanding of the latest genomic technology within the clinical setting, building confidence and an evidence base for continued use."


Bernard Courtieu, CEO of OncoDNA, commented:

"We are delighted to be partnering with Rutherford Health and in doing have designed a 'Framework for Genomics' that will influence and shape standards for biomarker testing across the UK private health system.  We plan to work with various stakeholders so that together we can broker improved access to biomarker testing and deliver the promise of precision medicine for cancer patients."


OncoDNA and Rutherford Health are committed to improving access to personalised oncology for as many patients as possible and have already secured reimbursement agreements from BUPA and other leading UK health insurers for easy access to these biomarker tests.

Rutherford Health's independent network currently consists of four cancer treatment centres in Newport, Reading, Bedlington and Liverpool and will draw patients from all over the UK, offering them consistent access to the latest tests to guide their treatment.

In addition to providing high energy proton beam therapy and conventional therapies such as chemotherapy, immunotherapy and radiotherapy, each Rutherford Cancer Centre also has state-of-the-art diagnostics including MRI and CT. The utilisation of OncoDNA's precision tests in these facilities will ensure that patients receive the highest possible standard of care.



For more information, please contact:


Rutherford Health plc

+44 (0) 16 3381 0661

Michael Moran, Chief Executive Officer
Marcus King, Finance Director



Grant Thornton (Corporate Adviser)

+44 (0) 20 7383 5100

Colin Aaronson / George Grainger




Instinctif Partners

+44 207 457 2020

Melanie Toyne-Sewell / Jeremy Durrant /

Rozi Morris



Media House International

07788 414 856 / 0207 710 0020

Ramsay Smith



About Rutherford Health plc

Rutherford Health plc is a leading UK provider of innovative cancer care. Operating a network of four state-of-the-art centres in WalesReadingNorthumberland and Liverpool, Rutherford Health offers a comprehensive range of the latest technology in cancer treatments, and is the only independent provider of proton beam therapy ("PBT") in the UK. The Company also provides conventional radiotherapy, chemotherapy, immunotherapy, imaging and wellbeing services.

The Group is listed on the Apex segment of the AQSE Growth Market under the symbol: RUTH. For more information, visit the Group's website:


About OncoDNA 

OncoDNA is a genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases. The company helps clinicians, academic researchers and biopharma companies to outsmart molecular complexity with the mission of delivering the promise of precision medicine. The company not only provides clinical guidance for the treatment and real-time monitoring of late stage cancer patients, but also supports research and drug development in cancer and genetic diseases. Since its early days in 2012, OncoDNA grew into a corporate group of companies with world-renown expertise. The Group offers a unique portfolio that combines NGS services, biomarker testing, data interpretation software, and clinical decision support tools. OncoDNA is headquartered in Belgium, and its entities - Biosequence and IntegraGen - are based in Spain, France and the United States. The Group employs over 100 employees across 9 countries, works with an international network of 35 distributors and collaborates with both European-based and US-based subcontracted accredited laboratories.

For further information, visit and connect with us on LinkedIn, Facebook or Twitter.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.